Olaparib is effective in combination with, and as maintenance therapy after, first-line endocrine therapy in prostate cancer cells.
Molecular Oncology
Feiersinger, Gertrud E GE; Trattnig, Kristina K; Leitner, Peter D PD; Guggenberger, Fabian F; Oberhuber, Alexander A; Peer, Sarah S; Hermann, Martin M; Skvortsova, Ira I; Vrbkova, Jana J; Bouchal, Jan J; Culig, Zoran Z; Santer, Frédéric R FR
Publication Date: 2018-04
Variant appearance in text: SECISBP2: 593C>T; T198I